Press release
Diabetic Retinopathy Market on Track for Major Expansion by 2034, According to DelveInsight | Novartis, Kodiak Sciences Inc., Regenxbio, Perfuse Therapeutics, Hoffmann-La Roche, Boehringer Ingelheim
DelveInsight's "Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Diabetic Retinopathy, historical and forecasted epidemiology as well as the Diabetic Retinopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Diabetic Retinopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Retinopathy Market Forecast [https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Diabetic Retinopathy Market Report:
*
The Diabetic Retinopathy market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In March 2024, OcuTerra Therapeutics, Inc., a clinical-stage ophthalmology company focused on developing innovative treatments for eye diseases, has announced topline results from its Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) trial for nesvategrast (OTT166), a selective RGD integrin inhibitor eye drop. The trial did not achieve its primary or key secondary efficacy endpoints. However, nesvategrast (OTT166 5%) demonstrated a favorable safety profile and was well tolerated, successfully meeting its primary safety endpoint. OcuTerra is now assessing strategic alternatives and will provide further updates in the future.
*
Diabetic retinopathy (DR) is a significant neurovascular complication of diabetes, causing blindness in adults who are in their working years. The American Academy of Ophthalmology reports that with diabetes affecting an estimated 387 million people globally, a number expected to increase to 592 million by 2035, DR impacts approximately 93 million individuals worldwide.
*
Diabetic retinopathy progresses through several stages: mild, where microaneurysms first appear; moderate, where blood vessels begin to lose their function; severe, involving blockages in blood vessels leading to the growth of new ones; and proliferative, the advanced stage characterized by the onset of new blood vessel formation.
*
The primary choices for initial treatment are three anti-VEGF medications: EYLEA (aflibercept), LUCENTIS (ranibizumab), and AVASTIN (bevacizumab).
*
Key Diabetic Retinopathy Companies: Novartis, Kodiak Sciences Inc., Regenxbio, Perfuse Therapeutics, Hoffmann-La Roche, Boehringer Ingelheim, RemeGen Co., Ltd., Jaeb Center for Health Research, Valo Health, Inc, EyePoint Pharmaceuticals, Novartis, AbbVie, and others
*
Key Diabetic Retinopathy Therapies: BEOVU, Tarcocimab tedromer, RGX-314, PER-001, Ranibizumab, Aflibercept (Eylea Registered ), RC28-E injection, Fenofibrate, OPL-0401 Dose 1, EYP-1901, Brolucizumab, RGX-314, and others
*
The Diabetic Retinopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Retinopathy pipeline products will significantly revolutionize the Diabetic Retinopathy market dynamics.
Diabetic Retinopathy Overview
Diabetic retinopathy is a complication of diabetes that affects the eyes. It occurs when high blood sugar levels damage the blood vessels in the retina, the light-sensitive tissue at the back of the eye. Over time, these damaged blood vessels may leak fluid or bleed, causing vision problems.
Get a Free sample for the Diabetic Retinopathy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/diabetic-retinopathy-market [https://www.delveinsight.com/report-store/diabetic-retinopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Diabetic Retinopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Diabetic Retinopathy Epidemiology Segmentation:
The Diabetic Retinopathy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Diabetic Retinopathy
*
Prevalent Cases of Diabetic Retinopathy by severity
*
Gender-specific Prevalence of Diabetic Retinopathy
*
Diagnosed Cases of Episodic and Chronic Diabetic Retinopathy
Download the report to understand which factors are driving Diabetic Retinopathy epidemiology trends @ Diabetic Retinopathy Epidemiology Forecast [https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Diabetic Retinopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Retinopathy market or expected to get launched during the study period. The analysis covers Diabetic Retinopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Diabetic Retinopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Diabetic Retinopathy Therapies and Key Companies
*
BEOVU: Novartis
*
Tarcocimab tedromer : Kodiak Sciences Inc.
*
RGX-314: Regenxbio
*
PER-001: Perfuse Therapeutics
*
Ranibizumab: Hoffmann-La Roche
*
Aflibercept (Eylea Registered ): Boehringer Ingelheim
*
RC28-E injection: RemeGen Co., Ltd.
*
Fenofibrate: Jaeb Center for Health Research
*
OPL-0401 Dose 1: Valo Health, Inc.
*
EYP-1901: EyePoint Pharmaceuticals
*
Brolucizumab: Novartis
*
RGX-314: AbbVie
Discover more about therapies set to grab major Diabetic Retinopathy market share @ Diabetic Retinopathy Treatment Landscape [https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Scope of the Diabetic Retinopathy Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Diabetic Retinopathy Companies: Novartis, Kodiak Sciences Inc., Regenxbio, Perfuse Therapeutics, Hoffmann-La Roche, Boehringer Ingelheim, RemeGen Co., Ltd., Jaeb Center for Health Research, Valo Health, Inc, EyePoint Pharmaceuticals, Novartis, AbbVie, and others
*
Key Diabetic Retinopathy Therapies: BEOVU, Tarcocimab tedromer, RGX-314, PER-001, Ranibizumab, Aflibercept (Eylea Registered ), RC28-E injection, Fenofibrate, OPL-0401 Dose 1, EYP-1901, Brolucizumab, RGX-314, and others
*
Diabetic Retinopathy Therapeutic Assessment: Diabetic Retinopathy current marketed and Diabetic Retinopathy emerging therapies
*
Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy market drivers and Diabetic Retinopathy market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Diabetic Retinopathy Unmet Needs, KOL's views, Analyst's views, Diabetic Retinopathy Market Access and Reimbursement
To know more about Diabetic Retinopathy companies working in the treatment market, visit @ Diabetic Retinopathy Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Diabetic Retinopathy Market Report Introduction
2. Executive Summary for Diabetic Retinopathy
3. SWOT analysis of Diabetic Retinopathy
4. Diabetic Retinopathy Patient Share (%) Overview at a Glance
5. Diabetic Retinopathy Market Overview at a Glance
6. Diabetic Retinopathy Disease Background and Overview
7. Diabetic Retinopathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Diabetic Retinopathy
9. Diabetic Retinopathy Current Treatment and Medical Practices
10. Diabetic Retinopathy Unmet Needs
11. Diabetic Retinopathy Emerging Therapies
12. Diabetic Retinopathy Market Outlook
13. Country-Wise Diabetic Retinopathy Market Analysis (2020-2034)
14. Diabetic Retinopathy Market Access and Reimbursement of Therapies
15. Diabetic Retinopathy Market Drivers
16. Diabetic Retinopathy Market Barriers
17. Diabetic Retinopathy Appendix
18. Diabetic Retinopathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetic-retinopathy-market-on-track-for-major-expansion-by-2034-according-to-delveinsight-novartis-kodiak-sciences-inc-regenxbio-perfuse-therapeutics-hoffmannla-roche-boehringer-ingelheim]
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Retinopathy Market on Track for Major Expansion by 2034, According to DelveInsight | Novartis, Kodiak Sciences Inc., Regenxbio, Perfuse Therapeutics, Hoffmann-La Roche, Boehringer Ingelheim here
News-ID: 3854566 • Views: …
More Releases from ABNewswire
DDC Is Blending Culture and Digital Structure to Serve the Modern Consumer Model …
Every major consumer sector eventually reaches a moment when the market stops rewarding trend cycles and starts rewarding truth. Apparel lived through it. Coffee lived through it. Wellness lived through it. Now food is entering that same transition, and DDC Enterprise Limited (NYSE American: DDC [https://ir.ddc.xyz/]) is standing directly in front of the shift.
The change is not only cultural. It is structural. And it arrives at a moment when consumers…
Canada Data Center Processor Market to Reach USD 1.45 Billion by 2030 Driven by …
Mordor Intelligence has published a new report on the Canada Data Center Processor Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Canada Data Center Processor Market Overview
The Canada Data Center Processor Market [https://www.mordorintelligence.com/industry-reports/canada-data-center-processor-market?utm_source=abnewswire] size reached USD 0.78 billion in 2025 and is projected to hit USD 1.45 billion by 2030, advancing at a 13.25% CAGR.
In terms of market dynamics, the Canada Data Center Processor Market share is…
TimeLuxury Introduces The Provenance Standard A New Benchmark for Trust in Pre-O …
As confidence in online luxury purchases grows-and so do concerns about authenticity-TimeLuxury is raising the bar with The Provenance Standard, a new framework designed to bring unprecedented transparency, integrity, and storytelling to the pre-owned Swiss watch market.
Unlike generic "certified pre-owned" claims, The Provenance Standard combines forensic-level authentication with rich, documented history. Every timepiece undergoes a rigorous 7-point verification: movement inspection by trained horologists, case and dial forensics, service record review,…
Reef Haven Sets New Industry Benchmark for Marine Livestock Safety with Medical …
Reef Haven elevates the Australian marine hobby with rigorous medical quarantine protocols for saltwater fish. Located in Melbourne, this aquarium store offers guaranteed healthy livestock, WYSIWYG corals, and premium supplies. Owner Hazel Lee provides peace of mind to enthusiasts nationwide, delivering disease-free animals and expert maintenance services for thriving reef tanks.
MELBOURNE, Victoria - Reef Haven, a specialist marine aquarium retailer located in Box Hill South, is redefining the standards of…
More Releases for Diabetic
Exploring The Diabetic Retinopathy Market In A Diabetic-Prevalent World: The Dri …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Diabetic Retinopathy Market Size Growth Forecast: What to Expect by 2025?
The diabetic retinopathy market has experienced robust expansion over the last few years, with projections indicating a rise from $8.61 billion in 2024 next year to $9.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of…
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
